<DOC>
	<DOCNO>NCT00003769</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy surgery may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness perillyl alcohol follow surgery treating patient stage II stage III pancreatic cancer .</brief_summary>
	<brief_title>Perillyl Alcohol Followed Surgery Treating Patients With Stage II Stage III Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess biologic activity perillyl alcohol patient potentially resectable , stage II stage III pancreatic adenocarcinoma . II . Characterize acute toxicity drug patient . III . Evaluate antitumor activity drug patient . IV . Monitor quantitate plasma level perillyl alcohol oral administration patient population . OUTLINE : Patients receive oral perillyl alcohol 4 time daily day 1-14 . Patients undergo surgical resection day 15 . There continuation perillyl alcohol postoperatively . Patients follow minimum 2 4 month follow surgery . PROJECTED ACCRUAL : A total 10 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Perilla alcohol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage II stage III pancreatic adenocarcinoma consider resectable Lesions amenable surgery curative intent Bidimensionally measurable evaluable disease No evidence metastatic disease No clinically detectable third space fluid collection ( e.g. , ascites effusion ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.5 g/dL Hepatic : Bilirubin great 4 time upper limit normal ( ULN ) PTT great 1.5 time control ( unless anticoagulant ) Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent serious systemic disorder incompatible study No active infection No second primary malignancy , previously untreated curative intent presently active , would preclude curative resection pancreas PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy pancreatic carcinoma Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pancreatic carcinoma Surgery : See Disease Characteristics Other : At least 1 month since prior investigational agent At least 72 hour since prior anticoagulant therapy , cholesterollowering agent ( e.g. , lovastatin ) , high dosage vitamin , antioxidants No concurrent anticoagulants except sole purpose central line patency maintenance No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>